Frontier IP's half-year profit rose 86% in dollars to the end of 2019 but its stocks are now under pressure in the current economic climate.

Lilly Asia Ventures, an investor in the cancer drug developer since its series A round, returned to back a series C that doubled its overall funding to $140m.

Dragonfly, whose co-founders include MIT and UC Berkeley faculty, has boosted its total financing to $300m in round of undisclosed size led by Fidelity.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Unilever Ventures returned to back a round led by Temasek that expanded the health and wellness services platform's overall financing to approximately $390m.

Celgene-backed immuno-oncology drug developer Dragonfly Therapeutics boosted its total financing to $300m in round of undisclosed size led by Fidelity.

University of Wisconsin-Madison gene medicine developer Design Therapeutics has attracted SR One for its series A round.

SR One led a round disclosed by the genetic medicine developer, a spinout of University of Wisconsin-Madison, as it emerged from stealth.

UC Berkeley's Nurix Therapeutics will use the capital to prepare two protein modulation-based immuno-oncology drugs for the clinic.

Celgene-backed Nurix Therapeutics will use the capital to advance two protein modulation-based immuno-oncology drug candidates toward clinical trials.